Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma

Maria Leimer, Amir Kurtaran, Peter Smith-Jones, Markus Raderer, Ernst Havlik, Peter Angelberger, Friedrich Vorbeck, Bruno Niederle, Christian Herold, Irene Virgolini

Research output: Contribution to journalArticle

Abstract

1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)- lanreotide is a universal somatostatin (SST) receptor subtype ligand that binds to a large variety of human tumors. We report the case of a patient with metastatic gastrinoma who was treated with 90Y-DOTA-lanreotide. Before treatment, dosimetry with 111In-DOTA-lanreotide (150 MBq, 10 nmol) indicated a dose of 5.8 mGy/MBq for the recurrent abdominal gastrinoma, and a mean dose of ≃1.0 mGy/MBq for liver metastases (i.e., 56 and ≃10 mGy/MBq for 90Y-DOTA-lanreotide, respectively). After four infusions of 90Y- DOTA-lanreotide (each 1 GBq, ≃30 nmol) over a 6-mo period, the 111In- DOTA-lanreotide scintigraphy of the liver had returned to a nearly normal condition and a remarkably decreased uptake by the recurrent gastrinoma was calculated (≃5 mGy/MBq for 90Y-DOTA-lanreotide). The imaging results were well-correlated with a 25% regression of the liver metastases as indicated by CT. Blood, urine and whole-body clearances of 111In-DOTA-lanreotide and 90Y-DOTA-lanreotide were very similar. The DOTA-lanreotide promises to be useful for functional tumor diagnosis (111In-DOTA-lanreotide) and receptor-mediated tumor radiotherapy (90Y-DOTA-lanreotide).

Original languageEnglish (US)
Pages (from-to)2090-2094
Number of pages5
JournalJournal of Nuclear Medicine
Volume39
Issue number12
Publication statusPublished - Dec 1998
Externally publishedYes

    Fingerprint

Keywords

  • DOTA-lanreotide
  • Gastrinoma
  • Somatostatin receptor
  • Tumor radiotherapy

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Leimer, M., Kurtaran, A., Smith-Jones, P., Raderer, M., Havlik, E., Angelberger, P., ... Virgolini, I. (1998). Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. Journal of Nuclear Medicine, 39(12), 2090-2094.